ReviewACS omega2025
Microneedles as Gateways: Smart Nanoparticle Delivery for Enhanced Breast Cancer Treatment.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Localized immunotherapy via dissolving microneedles for the prevention of breast cancer recurrence.Drug delivery and translational research · 2026Review
- Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a common and potentially fatal disease caused by the abnormal proliferation of cells in the breast tissue. This outlines the critical need for early detection and awareness for effective prevention and treatment. Current therapeutic approaches for breast cancer include surgery, chemotherapy, hormonal therapy, and radiation therapy. Even with the promising strides made in breast cancer research and the inevitable advent of new treatments and drugs, achieving optimal therapeutic outcomes remains challenging due to various obstacles. Treatment with side effects is one of the greatest challenges arising from nonspecificity, with multidrug resistance demanding prolonged doses to ensure patients' quality of life. Nanomedicine has emerged as a revolutionary approach for improving breast cancer therapy by leveraging nanoparticles for targeted drug delivery, enhanced biocompatibility and reduced systemic toxicity. Despite these advantages, nanoparticle-based therapies face challenges, including limited tumor penetration, off-target toxicity, and clinical translation barrier. To overcome these challenges, microneedle technology has been introduced as a minimally invasive, patient-friendly platform for localized drug delivery. MNs facilitate the direct transdermal administration of therapeutic agents, enhancing drug bioavailability at tumor sites while minimizing systemic side effects. The integration of NPs into MN systems represents a novel strategy to optimize cancer treatment by ensuring controlled and precise drug release. This review explores the role of nanoparticles in breast cancer therapy, the design and fabrication of MNs, and the synergies between these two technologies, while also addressing challenges in clinical translation, regulatory frameworks, and future perspectives in cancer nanomedicine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.